{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:49:45Z","timestamp":1791229785417,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00467-022-05652-9","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T08:03:30Z","timestamp":1656057810000},"page":"451-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome"],"prefix":"10.1007","volume":"38","author":[{"given":"Yuta","family":"Inoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-6961","authenticated-orcid":false,"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"5652_CR1","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","volume":"32","author":"K Kamei","year":"2017","unstructured":"Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071\u20132078. https:\/\/doi.org\/10.1007\/s00467-017-3718-0","journal-title":"Pediatr Nephrol"},{"key":"5652_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(14)60541-9","journal-title":"Lancet"},{"key":"5652_CR3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, Muller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, Haffner D, International Pediatric Nephrology Association (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529\u20131561. https:\/\/doi.org\/10.1007\/s00467-020-04519-1","journal-title":"Pediatr Nephrol"},{"key":"5652_CR4","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","volume":"15","author":"T Kelesidis","year":"2011","unstructured":"Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15:e2\u2013e16. https:\/\/doi.org\/10.1016\/j.ijid.2010.03.025","journal-title":"Int J Infect Dis"},{"key":"5652_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A, Ladomenou F (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab. Int Rev Immunol 36:352\u2013359. https:\/\/doi.org\/10.1080\/08830185.2017.1346092","journal-title":"Int Rev Immunol"},{"key":"5652_CR6","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1:e184169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"key":"5652_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers7010305","volume":"7","author":"J Worch","year":"2015","unstructured":"Worch J, Makarova O, Burkhardt B (2015) Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel) 7:305\u2013328. https:\/\/doi.org\/10.3390\/cancers7010305","journal-title":"Cancers (Basel)"},{"key":"5652_CR8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jpeds.2012.11.038","volume":"162","author":"M Kavcic","year":"2013","unstructured":"Kavcic M, Fisher BT, Seif AE, Li Y, Huang YS, Walker D, Aplenc R (2013) Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children\u2019s hospitals across the United States. J Pediatr 162:1252\u20131258. https:\/\/doi.org\/10.1016\/j.jpeds.2012.11.038","journal-title":"J Pediatr"},{"key":"5652_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","volume":"37","author":"Y Inoki","year":"2022","unstructured":"Inoki Y, Kamei K, Nishi K, Sato M, Ogura M, Ishiguro A (2022) Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr Nephrol 37:1057\u20131066. https:\/\/doi.org\/10.1007\/s00467-021-05304-4","journal-title":"Pediatr Nephrol"},{"key":"5652_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","volume":"35","author":"C Parmentier","year":"2020","unstructured":"Parmentier C, Delbet JD, Decramer S, Boyer O, Hogan J, Ulinski T (2020) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:455\u2013462. https:\/\/doi.org\/10.1007\/s00467-019-04398-1","journal-title":"Pediatr Nephrol"},{"key":"5652_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","volume":"24","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Tomii Y (2020) Profound effect of post-rituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome. Clin Exp Nephrol 24:386\u2013387. https:\/\/doi.org\/10.1007\/s10157-020-01858-z","journal-title":"Clin Exp Nephrol"},{"key":"5652_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.12998\/wjcc.v7.i9.1021","volume":"7","author":"P Marzuillo","year":"2019","unstructured":"Marzuillo P, Guarino S, Esposito T, Sessa AD, Orsini SI, Capalbo D, Giudice EMd, Manna AL (2019) Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values. World J Clin Cases 7:1021\u20131027. https:\/\/doi.org\/10.12998\/wjcc.v7.i9.1021","journal-title":"World J Clin Cases"},{"key":"5652_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5414\/CN108835","volume":"85","author":"S Fujinaga","year":"2016","unstructured":"Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T (2016) Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol 85:340\u2013345. https:\/\/doi.org\/10.5414\/CN108835","journal-title":"Clin Nephrol"},{"key":"5652_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","volume":"17","author":"AM Khojah","year":"2019","unstructured":"Khojah AM, Miller ML, Klein-Gitelman MS, Curran ML, Hans V, Pachman LM, Fuleihan RL (2019) Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol Online J 17:61. https:\/\/doi.org\/10.1186\/s12969-019-0365-y","journal-title":"Pediatr Rheumatol Online J"},{"key":"5652_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12185-010-0528-6","volume":"91","author":"E Irie","year":"2010","unstructured":"Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T (2010) Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 91:501\u2013508. https:\/\/doi.org\/10.1007\/s12185-010-0528-6","journal-title":"Int J Hematol"},{"key":"5652_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","volume":"18","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY (2019) Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review. Autoimmun Rev 18:535\u2013541. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.010","journal-title":"Autoimmun Rev"},{"key":"5652_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD (2013) Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13:106\u2013111. https:\/\/doi.org\/10.1016\/j.clml.2012.11.011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5652_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1081-1206(10)60665-5","volume":"99","author":"S Agarwal","year":"2007","unstructured":"Agarwal S, Cunningham-Rundles C (2007) Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol 99:281\u2013283. https:\/\/doi.org\/10.1016\/S1081-1206(10)60665-5","journal-title":"Ann Allergy Asthma Immunol"},{"key":"5652_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"28","author":"M Sato","year":"2013","unstructured":"Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28:145\u2013149. https:\/\/doi.org\/10.1007\/s00467-012-2286-6","journal-title":"Pediatr Nephrol"},{"key":"5652_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","volume":"50","author":"X Mariette","year":"2011","unstructured":"Mariette X, Gottenberg JE, Ravaud P, Combe B (2011) Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 50:222\u2013229. https:\/\/doi.org\/10.1093\/rheumatology\/keq368","journal-title":"Rheumatology (Oxford)"},{"key":"5652_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/ckj\/sfx014","volume":"10","author":"S Shah","year":"2017","unstructured":"Shah S, Jaggi K, Greenberg K, Geetha D (2017) Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Kidney J 10:470\u2013474. https:\/\/doi.org\/10.1093\/ckj\/sfx014","journal-title":"Clin Kidney J"},{"key":"5652_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2474-15-178","volume":"15","author":"H Marco","year":"2014","unstructured":"Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, Chaudhry AN, Smith KG, Jayne DR (2014) The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 15:178. https:\/\/doi.org\/10.1186\/1471-2474-15-178","journal-title":"BMC Musculoskelet Disord"},{"key":"5652_CR23","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896\u20133908. https:\/\/doi.org\/10.1002\/art.23059","journal-title":"Arthritis Rheum"},{"key":"5652_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/rheumatology\/key306","volume":"58","author":"L Kearsley-Fleet","year":"2019","unstructured":"Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, De Cock D, Foster HE, Southwood TR, Thomson W, Hyrich KL (2019) Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. Rheumatology (Oxford) 58:331\u2013335. https:\/\/doi.org\/10.1093\/rheumatology\/key306","journal-title":"Rheumatology (Oxford)"},{"key":"5652_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3899\/jrheum.140863","volume":"42","author":"A Tambralli","year":"2015","unstructured":"Tambralli A, Beukelman T, Cron RQ, Stoll ML (2015) Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol 42:541\u2013546. https:\/\/doi.org\/10.3899\/jrheum.140863","journal-title":"J Rheumatol"},{"key":"5652_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jiph.2018.09.006","volume":"12","author":"K Alfakeekh","year":"2019","unstructured":"Alfakeekh K, Azar M, Sowailmi BA, Alsulaiman S, Makdob SA, Omair A, Albanyan E, Bawazeer MS (2019) Immunosuppressive burden and risk factors of infection in primary childhood nephrotic syndrome. J Infect Public Health 12:90\u201394. https:\/\/doi.org\/10.1016\/j.jiph.2018.09.006","journal-title":"J Infect Public Health"},{"key":"5652_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1440-1797.2012.01650.x","volume":"17","author":"CC Wei","year":"2012","unstructured":"Wei CC, Yu IW, Lin HW, Tsai AC (2012) Occurrence of infection among children with nephrotic syndrome during hospitalizations. Nephrology (Carlton) 17:681\u2013688. https:\/\/doi.org\/10.1111\/j.1440-1797.2012.01650.x","journal-title":"Nephrology (Carlton)"},{"key":"5652_CR28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJMoa1405870","volume":"372","author":"S Jain","year":"2015","unstructured":"Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH, Zhu Y, Patel A, Hymas W, Chappell JD, Kaufman RA, Kan JH, Dansie D, Lenny N, Hillyard DR, Haynes LM, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, Wunderink RG, Edwards KM, Pavia AT, McCullers JA, Finelli L, CDC EPIC Study Team (2015) Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 372:835\u2013845. https:\/\/doi.org\/10.1056\/NEJMoa1405870","journal-title":"N Engl J Med"},{"key":"5652_CR29","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1016\/j.vaccine.2020.11.004","volume":"38","author":"Y Sun","year":"2020","unstructured":"Sun Y, Li H, Pei Z, Wang S, Feng J, Xu L, Gao P, Cao B, Zhan S (2020) Incidence of community-acquired pneumonia in urban China: a national population-based study. Vaccine 38:8362\u20138370. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.004","journal-title":"Vaccine"},{"key":"5652_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","volume":"39","author":"DE Furst","year":"2009","unstructured":"Furst DE (2009) Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 39:18\u201329. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.05.002","journal-title":"Semin Arthritis Rheum"},{"key":"5652_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.23171","volume":"58","author":"RJ Looney","year":"2008","unstructured":"Looney RJ, Srinivasan R, Calabrese LH (2008) The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 58:5\u201314. https:\/\/doi.org\/10.1002\/art.23171","journal-title":"Arthritis Rheum"},{"key":"5652_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR (2015) Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 57:24\u201329. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.004","journal-title":"J Autoimmun"},{"key":"5652_CR33","unstructured":"Department of Health and Social Care (2011) Clinical guidelines for immunoglobulin use: second edition update. https:\/\/www.gov.uk\/government\/publications\/clinical-guidelines-for-immunoglobulin-use-second-edition-update. Accessed 30 October 2021"},{"key":"5652_CR34","doi-asserted-by":"publisher","first-page":"e2036321","DOI":"10.1001\/jamanetworkopen.2020.36321","volume":"4","author":"CL McAtee","year":"2021","unstructured":"McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB (2021) Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4:e2036321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.36321","journal-title":"JAMA Netw Open"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05652-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05652-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05652-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T09:10:46Z","timestamp":1671441046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05652-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5652"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05652-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"6 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the National Center for Child Health and Development (approval number: 2021\u2013169).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent regarding participation was exempted in accordance with the principles of the Declaration of Helsinki and the ethical guidelines issued by the Ministry of Health, Labor, and Welfare, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for publication was exempted in accordance with the guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Koichi Kamei has obtained research funding from Public Foundation of Vaccination Research Center, the Terumo Foundation for Life Sciences and Arts, and Taiju Life Social Welfare Foundation; donations from Chugai Pharmaceutical Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Teijin Pharma Ltd., Shionogi Co. Ltd., and Otsuka Pharmaceutical Co. Ltd.; and lecture fees from Tanabe Mitsubishi Pharma, Baxter Ltd., and Zenyaku Kogyo Co. Ltd. All other authors have no potential conflicts of interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}